PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes.
Follo
M Y
MY
Finelli
C
C
Bosi
C
C
Martinelli
G
G
Mongiorgi
S
S
Baccarani
M
M
Manzoli
L
L
Blalock
W L
WL
Martelli
A M
AM
Cocco
L
L
D001374:Azacitidine / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000378:metabolism*; D010716:Phosphatidylinositols / Q000378:metabolism*; D054799:Phospholipase C beta / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*
D004791:Enzyme Inhibitors; D010716:Phosphatidylinositols; D051057:Proto-Oncogene Proteins c-akt; C518033:PLCB1 protein, human; D054799:Phospholipase C beta; D001374:Azacitidine